phrykt

Transcode Therapeutics, Inc. (RNAZ): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of RNAZ were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No RNAZ insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RNAZ short interest

Low short interest. 0.3% of RNAZ shares are sold short: about 1 share in 326. Over the last 12 reports the number of shares short went up 43%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 52,014 RNAZ shares were sold short, 0.3% of the shares outstanding, down 5.4% from the report before. At the average daily volume of 26,532 shares, buying them all back would take about 2.0 trading days (days to cover).

Shares short, % of all shares

0.31%May 15Oct 307.06%

Days to cover

2.0May 15Oct 304.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202652,0140.31%-5%26,5322.0
Oct 15, 202654,9680.32%+6%40,4621.4
Sep 30, 202652,0620.31%-15%68,4251.0
Sep 15, 202661,4030.36%+34%33,8201.8
Aug 31, 202645,9780.27%+49%122,4891.0
Aug 14, 202630,9100.18%+9%20,4071.5
Jul 31, 202628,2523.08%-18%15,4741.8
Jul 15, 202634,4463.76%-35%41,2871.0
Jun 30, 202652,8235.76%-7%20,3942.6
Jun 15, 202656,5276.16%+101%230,7351.0
May 29, 202628,1423.07%-22%15,0891.9
May 15, 202636,2653.95%+1%8,9134.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Transcode Therapeutics company events

Transcode Therapeutics filed 21 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Oct 28, 2026.

  1. Oct 28, 2026AnnouncementTransCode Therapeutics, Inc. issued a press release announcing that its board of directors has initiated a formal strategic process to evaluate opportunities designed to maximize the value of the Company and its oncology portfolio, including its lead product candidate, TTX-MC138. Filing
  2. Oct 1, 2026AgreementAs previously disclosed by TransCode Therapeutics, Inc. in a Current Report on Form 8-K filed with the Securities and Exchange Commission on April 7, 2026, the Company entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., a Cayman Islands exempt limited partnership dated as of April… Filing
  3. Sep 28, 2026AnnouncementTransCode Therapeutics, Inc. issued a press release announcing updated clinical data from its Phase 1a dose clinical trial of TTX-MC138. Filing
  4. Sep 11, 2026LeadershipTransCode Therapeutics, Inc. announced that Thomas A. Fitzgerald, M.B.A. had resigned as Chief Financial Officer, principal financial officer and principal accounting officer of the Company, and as a member of the Board of Directors of the Company, as well as from all other officer and director… Filing
  5. Aug 3, 2026SharesChanged the rights of its shareholders. Filing
  6. Jul 20, 2026VoteReported shareholder vote results. Filing
  7. Jul 17, 2026SharesChanged the rights of its shareholders. Filing
  8. Jul 2, 2026AnnouncementTransCode Therapeutics, Inc. commenced its 2026 Annual Meeting of Stockholders, as previously scheduled, and adjourned the Annual Meeting until July 20, 2026, at 9:30 a.m., Eastern Time. Filing
  9. Jun 18, 2026AnnouncementShared information with investors. Filing
  10. Jun 3, 2026AnnouncementTransCode Therapeutics, Inc. issued a press release announcing further results of its Phase 1a dose escalation clinical trial with TTX-MC138. Filing
  11. Jun 1, 2026VoteSet dates for shareholder nominations. Filing
  12. May 26, 2026ListingAmended an earlier report. TransCode Therapeutics, Inc. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Filing
  13. May 22, 2026ListingTransCode Therapeutics, Inc. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Filing
  14. Apr 7, 2026AgreementTransCode Therapeutics, Inc., a Delaware corporation, entered into a Standby Equity Purchase Agreement with YA II PN, LTD, a Cayman Islands exempt limited partnership, pursuant to which the Company has the right to sell to Yorkville up to $14 million of shares of the Company’s common stock, par… Filing
  15. Mar 3, 2026AnnouncementOf this Current Report is incorporated by reference into this Item 3.02. Filing
  16. Feb 23, 2026AnnouncementShared information with investors. Filing
  17. Feb 5, 2026AnnouncementShared information with investors. Filing
  18. Jan 6, 2026AnnouncementShared information with investors. Filing
  19. Dec 23, 2025AnnouncementAmended an earlier report. Risks Related to the Acquisition and Investment There are a number of risks related to the Acquisition and Investment, including the risk factors enumerated below. Filing
  20. Dec 22, 2025LeadershipThe Board of Directors of TransCode Therapeutics, Inc., a Delaware corporation, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Jack Stover to the Board, effective December 19, 2025. Filing
  21. Dec 11, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Transcode Therapeutics financials

Famous investors that hold RNAZ

1 of the 50 well-known investors we track reported holding RNAZ in their latest 13F filing. The largest position is Ken Griffin's, worth $17.1K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202610,207$17.1K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Transcode Therapeutics, Inc. (RNAZ) stock

Are RNAZ insiders buying or selling?

No RNAZ insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in RNAZ?

As of Oct 30, 2026, 52,014 RNAZ shares were sold short, 0.3% of the shares outstanding, down 5.4% from the report before. At the average daily volume of 26,532 shares, buying them all back would take about 2.0 trading days (days to cover). See the history.

Which famous investors hold RNAZ?

1 of the 50 well-known investors we track reported RNAZ in their latest 13F filing, including Ken Griffin. The largest position is worth $17.1K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.